Sally Kilbride
About
Sally Kilbride is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cardiology and Cardiovascular Medicine.
According to data from OpenAlex, Sally Kilbride has authored 36 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 19 papers in Physiology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Sally Kilbride's work include Chronic Obstructive Pulmonary Disease (COPD) Research (34 papers), Asthma and respiratory diseases (19 papers) and Inhalation and Respiratory Drug Delivery (15 papers). Sally Kilbride is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (34 papers), Asthma and respiratory diseases (19 papers) and Inhalation and Respiratory Drug Delivery (15 papers). Sally Kilbride collaborates with scholars based in United States, United Kingdom and Denmark. Sally Kilbride's co-authors include Fernando J. Martínez, Alison Church, Dave Singh, Maggie Tabberer, Rashmi Mehta, Robert A. Wise, Mark T. Dransfield, David A. Lipson, Chris Kalberg and David Halpin and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.
In The Last Decade
Sally Kilbride
36 papers receiving 1.7k citations
Hit Papers
Peers
Sally Kilbride
Noushin Brealey United Kingdom
Jean Brooks United States
Frank Barnhart United States
Lucy Frith United Kingdom
Earl St. Rose United States
Marcia L. Erbland United States
Chang‐Qing Zhu United Kingdom
Pilar Román Sánchez Spain
Nassrin Payvandi United Kingdom
Melissa Clarke Australia
Citations per year, relative to Sally Kilbride Sally Kilbride (= 1×)
peers
Noushin Brealey
Countries citing papers authored by Sally Kilbride
Since
Specialization
Citations
This map shows the geographic impact of Sally Kilbride's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally Kilbride with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally Kilbride more than expected).
Fields of papers citing papers by Sally Kilbride
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sally Kilbride. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally Kilbride. The network helps show where Sally Kilbride may publish in the future.
Co-authorship network of co-authors of Sally Kilbride
This figure shows the co-authorship network connecting the top 25 collaborators of Sally Kilbride. A scholar is included among the top collaborators of Sally Kilbride based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally Kilbride. Sally Kilbride is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Han, MeiLan K., Gerard J. Criner, Mark T. Dransfield, et al.. (2021). Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research. 7(1). 663–2020.
2.
Han, MeiLan K., Gerard J. Criner, Mark T. Dransfield, et al.. (2020). The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 202(9). 1237–1243.
3.
Lipson, David A., Courtney Crim, Gerard J. Criner, et al.. (2020). Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 201(12). 1508–1516.
4.
Halpin, David, Mark T. Dransfield, MeiLan K. Han, et al.. (2020). The effect of exacerbation history on outcomes in the IMPACT trial. European Respiratory Journal. 55(5). 1901921–1901921.
5.
Dransfield, Mark T., Courtney Crim, Gerard J. Criner, et al.. (2020). Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. Annals of the American Thoracic Society. 18(5). 788–798.
6.
Day, Nicola C., Gerard J. Criner, Mark T. Dransfield, et al.. (2020). Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respiratory Research. 21(1). 139–139.
7.
Tabberer, Maggie, Christine Jones, Sally Kilbride, et al.. (2020). Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. Advances in Therapy. 37(9). 3775–3790.
8.
Marı́n, José M., José Echave-Sustaeta, Sergi Pascual-Guàrdia, et al.. (2020). Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT. Therapeutic Advances in Respiratory Disease. 14. 3272698061–3272698061.
9.
Hanania, Nicola A., David M. Mannino, Gerard J. Criner, et al.. (2020). Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD. CHEST Journal. 159(3). 985–995.
10.
Kato, Motokazu, Keisuke Tomii, Kenichi Hashimoto, et al.. (2019). <p>The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population</p>. International Journal of COPD. Volume 14. 2849–2861.
11.
Lipson, David A., Gerard J. Criner, Mark T. Dransfield, et al.. (2019). The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety. Research at the University of Copenhagen (University of Copenhagen). A3334–A3334.
12.
Lipson, David A., Frank Barnhart, Noushin Brealey, et al.. (2018). Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine. 378(18). 1671–1680.
13.
Calverley, Peter M.A., Julie A. Anderson, Robert D. Brook, et al.. (2017). Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. American Journal of Respiratory and Critical Care Medicine. 197(1). 47–55.
14.
Crim, Courtney, Peter M.A. Calverley, Julie A. Anderson, et al.. (2017). Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. Respiratory Medicine. 131. 27–34.
15.
Martínez, Fernando J., Jørgen Vestbo, Julie A. Anderson, et al.. (2016). Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine. 195(7). 881–888.
16.
Donohue, James F., et al.. (2016). Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. Respiratory Medicine. 112. 65–74.
17.
Celli, Bartolomé R., Glenn Crater, Sally Kilbride, et al.. (2014). Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD. CHEST Journal. 145(5). 981–991.
18.
Martínez, Fernando J., Joseph Boscia, Gregory Feldman, et al.. (2013). Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial. Respiratory Medicine. 107(4). 550–559.
19.
Donohue, James F., M. Reza Maleki-Yazdi, Sally Kilbride, et al.. (2013). Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respiratory Medicine. 107(10). 1538–1546.
20.
Bateman, Eric, Gregory Feldman, Sally Kilbride, et al.. (2012). Efficacy and safety of the long‐acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. The Clinical Respiratory Journal. 6(4). 248–257.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Noushin Brealey Breakdown of academic impact, for papers by Jean Brooks Breakdown of academic impact, for papers by Frank Barnhart Breakdown of academic impact, for papers by Lucy Frith Breakdown of academic impact, for papers by Earl St. Rose Breakdown of academic impact, for papers by Marcia L. Erbland Breakdown of academic impact, for papers by Chang‐Qing Zhu Breakdown of academic impact, for papers by Pilar Román Sánchez Breakdown of academic impact, for papers by Nassrin Payvandi Breakdown of academic impact, for papers by Melissa Clarke